AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 72
Study 34803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 72
Study 34803760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol Cigarettes
Number of subjects: 0
Study 34803760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34803777 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 124
Study 34803851 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing left beta/theta power ratio NF training in combination with reducing right beta/theta power ratio NF training
Number of subjects: 0
Study 34803851 — intervention group
Group type: COMPARATOR
Intervention: Sham NF training
Number of subjects: 0
Study 34803867 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 34804205 — intervention group
Group type: EXPERIMENTAL
Intervention: Field Assessment Stroke Triage for Emergency Destination ⩾4
Number of subjects: 200
Study 34804205 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based stroke triage
Number of subjects: 200
Study 34804358 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne lesion extraction every two weeks
Number of subjects: 140
Study 34804358 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline 100mg once daily
Number of subjects: 140
Study 34804358 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1 alpha expression
Number of subjects: 140
Study 34804608 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-inclusive sulfonylurea
Number of subjects: 60
Study 34804608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea(s) monotherapy
Number of subjects: 60
Study 34804608 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 controls)
Number of subjects: 60
Study 34804608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic parkinsonian patients
Number of subjects: 60
Study 34804608 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 controls)
Number of subjects: 60
Study 34804608 — intervention group
Group type: EXPERIMENTAL
Intervention: All parkinsonian patients
Number of subjects: 60
Study 34804848 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg weekly
Number of subjects: 547
Study 34804848 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's prognosis
Number of subjects: 547
Study 34804848 — intervention group
Group type: EXPERIMENTAL
Intervention: MSKCC score
Number of subjects: 547
Study 34804993 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of virulent bacteria in the gut microbiota of the patient with advanced colorectal tumor.
Number of subjects: 2
Study 34804993 — intervention group
Group type: COMPARATOR
Intervention: Healthy twin sister's gut microbiota composition.
Number of subjects: 2
Study 34805034 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching with Parents
Number of subjects: 0
Study 34805034 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34805058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet
Number of subjects: 0
Study 34805058 — intervention group
Group type: COMPARATOR
Intervention: Non-adherence to the Mediterranean diet
Number of subjects: 0
Study 34805212 — intervention group
Group type: EXPERIMENTAL
Intervention: Position change from the bed to a wheelchair
Number of subjects: 0
Study 34805212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34805240 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Vitamin E levels
Number of subjects: 0
Study 34805240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34805629 — intervention group
Group type: EXPERIMENTAL
Intervention: CathPR (catheter port reversal)
Number of subjects: 23
Study 34805632 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 (5-Lipoxygenase Activating Protein Inhibitor)
Number of subjects: 632
Study 34805632 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 plus dapagliflozin (10 mg/d)
Number of subjects: 632
Study 34805632 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718
Number of subjects: 632
Study 34805632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 34805723 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet (50 g/1000 kcal per day)
Number of subjects: 0
Study 34805723 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain diet (macronutrient-matched)
Number of subjects: 0
Study 34806137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical corticosteroids (TCS)
Number of subjects: 0
Study 34806137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus TCS
Number of subjects: 0
Study 34806137 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 0
Study 34806155 — intervention group
Group type: EXPERIMENTAL
Intervention: GB242
Number of subjects: 570
Study 34806155 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (INF)
Number of subjects: 570
Study 34806163 — intervention group
Group type: EXPERIMENTAL
Intervention: GELAD chemotherapy regimen (gemcitabine 1.0 g/m²)
Number of subjects: 0
Study 34806163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwiched radiotherapy
Number of subjects: 0
Study 34806762 — intervention group
Group type: COMPARATOR
Intervention: Renal denervation
Number of subjects: 1416
Study 34806912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraoperative CSF pressure monitoring during surgical decompression
Number of subjects: 0
Study 34806912 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 0
Study 34806998 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education through a CKD campaign facilitated by a nephrologist and mHealth (periodic mobile phone calls) from community health workers
Number of subjects: 126
Study 34806998 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 126
Study 34806997 — intervention group
Group type: EXPERIMENTAL
Intervention: AFib 2gether mobile app
Number of subjects: 37
Study 34807306 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D biplane ultrasound imaging
Number of subjects: 0
Study 34807306 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2D ultrasound imaging
Number of subjects: 0
Study 34807657 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABMT
Number of subjects: 145
Study 34807657 — intervention group
Group type: COMPARATOR
Intervention: Sham ABMT
Number of subjects: 145
Study 34807657 — intervention group
Group type: COMPARATOR
Intervention: Assessments only
Number of subjects: 145
Study 34807722 — intervention group
Group type: EXPERIMENTAL
Intervention: Management without anticoagulation
Number of subjects: 266
Study 34807883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 75
Study 34807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 124
Study 34807979 — intervention group
Group type: COMPARATOR
Intervention: Control (no rivaroxaban)
Number of subjects: 124
Study 34807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline biomarkers
Number of subjects: 124
Study 34807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors vs. those who died
Number of subjects: 124
Study 34807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 124
Study 34807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 124
Study 34807989 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 1973
Study 34808103 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of glycemic markers
Number of subjects: 2290
Study 34808524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of six molecularly targeted agents and a PD-L1 antagonist
Number of subjects: 140
Study 34808624 — intervention group
Group type: EXPERIMENTAL
Intervention: rhythmic speech-language therapy (rSLT)
Number of subjects: 44
Study 34808624 — intervention group
Group type: EXPERIMENTAL
Intervention: rhythmic balance-mobility training (rBMT)
Number of subjects: 44
Study 34808624 — intervention group
Group type: COMPARATOR
Intervention: no-therapy (NT)
Number of subjects: 44
Study 34808624 — intervention group
Group type: COMPARATOR
Intervention: healthy controls (HC)
Number of subjects: 44
Study 34808697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant growth hormone (GH) in IVF
Number of subjects: 1352
Study 34808697 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1352
Study 34809482 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Technology Education for Pumps and Pens
Number of subjects: 0
Study 34809507 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban discontinuation prior to surgery
Number of subjects: 0
Study 34809507 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34809579 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire
Number of subjects: 59
Study 34809579 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 59
Study 34809579 — intervention group
Group type: COMPARATOR
Intervention: Emergence delirium (ED) group
Number of subjects: 59
Study 34809579 — intervention group
Group type: EXPERIMENTAL
Intervention: Watcha scale score
Number of subjects: 59
Study 34809579 — intervention group
Group type: EXPERIMENTAL
Intervention: PAED scale score
Number of subjects: 59
Study 34809974 — intervention group
Group type: EXPERIMENTAL
Intervention: Total folate intake up to 1,200 μg/d
Number of subjects: 552
Study 34809974 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental folate intake up to 800 μg/d
Number of subjects: 552
Study 34810040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (walking/cycling facilities)
Number of subjects: 2478
Study 34810040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (land use mix-diversity)
Number of subjects: 2478
Study 34810040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (aesthetics)
Number of subjects: 2478
Study 34810040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (safety from traffic)
Number of subjects: 2478
Study 34810067 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC1 patients
Number of subjects: 30
Study 34810067 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 34810184 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 675
Study 34810184 — intervention group
Group type: COMPARATOR
Intervention: Matched references
Number of subjects: 675
Study 34810187 — intervention group
Group type: EXPERIMENTAL
Intervention: VRi vestibular rehabilitation intervention based on the conventional Cawthorne-Cooksey protocol
Number of subjects: 30
Study 34810187 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cawthorne-Cooksey protocol
Number of subjects: 30
Study 34810187 — intervention group
Group type: EXPERIMENTAL
Intervention: VRi vestibular rehabilitation intervention
Number of subjects: 30
Study 34810193 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week interactive informational mobile health intervention on COVID-19 prevention practices
Number of subjects: 385
Study 34810276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 274
Study 34810276 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 274
Study 34811954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 425
Study 34811954 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (control)
Number of subjects: 425
Study 34812195 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive recharge burst spinal cord stimulation (B-SCS)
Number of subjects: 0
Study 34812733 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 20
Study 34812733 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiki
Number of subjects: 20
Study 34812733 — intervention group
Group type: COMPARATOR
Intervention: Focus groups
Number of subjects: 20
Study 34812733 — intervention group
Group type: COMPARATOR
Intervention: Wikis
Number of subjects: 20
Study 34812928 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task (PASAT) training
Number of subjects: 46
Study 34813044 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 480
Study 34813082 — intervention group
Group type: EXPERIMENTAL
Intervention: Active information provision
Number of subjects: 8389
Study 34813082 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive information provision
Number of subjects: 8389
Study 34813191 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS algorithm for diagnosing AHF
Number of subjects: 103
Study 34813486 — intervention group
Group type: EXPERIMENTAL
Intervention: VR treatment (self-guided, mobile app-based VR CBT)
Number of subjects: 54
Study 34813486 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 54
Study 34813485 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° VR video
Number of subjects: 32
Study 34813485 — intervention group
Group type: COMPARATOR
Intervention: 2D video
Number of subjects: 32
Study 34813491 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 21
Study 34813491 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care workers' involvement in iCBT
Number of subjects: 21
Study 34813506 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL infusion products
Number of subjects: 26
Study 34813516 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain (pain events, duration, severity)
Number of subjects: 345
Study 34813516 — intervention group
Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 345
Study 34813516 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 345
Study 34813516 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain presence
Number of subjects: 345
Study 34813516 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pain events
Number of subjects: 345
Study 34813579 — intervention group
Group type: EXPERIMENTAL
Intervention: Visby STI Panel
Number of subjects: 55
Study 34813579 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care clinic results
Number of subjects: 55
Study 34813910 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW) plus usual care
Number of subjects: 14752
Study 34813910 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 14752
Study 34814152 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum adipsin concentration
Number of subjects: 908
Study 34814152 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum adipsin levels
Number of subjects: 908
Study 34814152 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating adipsin
Number of subjects: 908
Study 34814152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model of NAFLD remission
Number of subjects: 908
Study 34814185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral targeted therapy
Number of subjects: 2
Study 34814190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Age (GA) ≤35 weeks
Number of subjects: 16462
Study 34814190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Age (GA) ≥42 weeks
Number of subjects: 16462
Study 34814190 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys within multiple GA intervals
Number of subjects: 16462
Study 34814868 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based 6-week self-management supportive care program, Cancer Thriving and Surviving
Number of subjects: 0
Study 34814868 — intervention group
Group type: COMPARATOR
Intervention: Education attention control
Number of subjects: 0
Study 34814922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary biomarker-Mediterranean diet score
Number of subjects: 642
Study 34814935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (0.1 to 0.2 mg/kg/h, 2.4 to 4.8 mg/kg/day) with standard therapy
Number of subjects: 84
Study 34814935 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (lopinavir/ritonavir, hydroxychloroquine, oxygen therapy, non-invasive and invasive ventilator, antibiotic therapy, renal-replacement therapy, ECMO)
Number of subjects: 84
Study 34814935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate
Number of subjects: 84
Study 34815285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 664
Study 34815285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 34815321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) exposure during pregnancy
Number of subjects: 345
Study 34815321 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 345
Study 34815326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS) findings
Number of subjects: 215
Study 34815326 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS findings
Number of subjects: 215
Study 34815632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single patient classifier (SPC)
Number of subjects: 875
Study 34815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 459
Study 34815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 459
Study 34815708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 34815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 459
Study 34815790 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound blood-brain barrier disruption
Number of subjects: 0
Study 34816187 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARThealth intervention
Number of subjects: 0
Study 34816187 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 34816248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 34816288 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 946
Study 34816288 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 946
Study 34816294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg methylprednisolone and 5 mg/day ruxolitinib
Number of subjects: 39
Study 34816730 — intervention group
Group type: EXPERIMENTAL
Intervention: Early staged PCI (<4 weeks)
Number of subjects: 1432
Study 34816730 — intervention group
Group type: COMPARATOR
Intervention: Late staged PCI (≥4 weeks)
Number of subjects: 1432
Study 34817381 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 396
Study 34817381 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint analysis experiment
Number of subjects: 396
Study 34817381 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes of hypothetical research studies
Number of subjects: 396
Study 34817393 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise sessions (24 sessions over 2 months)
Number of subjects: 30
Study 34817414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (granules/dispersible tablets)
Number of subjects: 0
Study 34817414 — intervention group
Group type: COMPARATOR
Intervention: Conventional dolutegravir tablets (50 mg and 25 mg)
Number of subjects: 0
Study 34817414 — intervention group
Group type: COMPARATOR
Intervention: Adult FDC of abacavir/dolutegravir/lamivudine and dolutegravir/lamivudine
Number of subjects: 0
Study 34817420 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine premedication
Number of subjects: 9497
Study 34817420 — intervention group
Group type: COMPARATOR
Intervention: No benzodiazepine premedication
Number of subjects: 9497
Study 34817751 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 20
Study 34817751 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 34817837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 surgical volume
Number of subjects: 1423
Study 34817837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 treatment of benign/precursors diseases
Number of subjects: 1423
Study 34817837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 treatment of neuroendocrine tumors
Number of subjects: 1423
Study 34817837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 laparoscopic procedures
Number of subjects: 1423
Study 34817837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 robot-assisted procedures
Number of subjects: 1423
Study 34817837 — intervention group
Group type: COMPARATOR
Intervention: Post-operative intensive care unit accesses
Number of subjects: 1423
Study 34817837 — intervention group
Group type: COMPARATOR
Intervention: Post-operative mortality
Number of subjects: 1423
Study 34817851 — intervention group
Group type: COMPARATOR
Intervention: n-3 polyunsaturated fatty acids (n-3PUFAs)
Number of subjects: 1924
Study 34818097 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34818379 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole treatment
Number of subjects: 70
Study 34818478 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) 120 mg daily
Number of subjects: 0
Study 34818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period A (2000 to 2005)
Number of subjects: 1996
Study 34818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period B (2006 to 2011)
Number of subjects: 1996